Forte Biosciences (FBRX)

• Market cap: $124M
• 1 day: 3.64%
• 5 days: -16.10%
• 1 month: 42.73%
• 3 months: 173.16%
• 6 months: 54.72%
• Year to date: -6.80%
• 1 year: 4.54%
• 5 years: -95.40%
• 10 years: -95.40%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).

Employees: 11

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1.89% less ownership

Funds ownership: 52.34% [Q2] → 50.45% (-1.89%) [Q3]

30% less funds holding

Funds holding: 33 [Q2] → 23 (-10) [Q3]

60% less capital invested

Capital invested by funds: $10.2M [Q2] → $4.12M (-$6.13M) [Q3]

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 20

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $64 231% upside
• Avg. target: $64 231% upside
• High target: $64 231% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Chardan Capital Daniil Gataulin 25% 1-year accuracy 8 / 32 met price target

231% upside $64

Buy Maintained

4 Dec 2024